These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18473811)

  • 21. The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma.
    Choueiri TK; Bukowski RM; Rini BI
    Semin Oncol; 2006 Oct; 33(5):596-606. PubMed ID: 17045089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma.
    Ainsworth NL; Lee JS; Eisen T
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1793-805. PubMed ID: 19954291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
    Albiges L; Salem M; Rini B; Escudier B
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advanced renal cell carcinoma: current and emerging management strategies.
    Escudier B
    Drugs; 2007; 67(9):1257-64. PubMed ID: 17547470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [New drugs for metastatic kidney cancer].
    Doehn C
    Aktuelle Urol; 2008 Jan; 39(1):41-52. PubMed ID: 18228187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Will the dark sky over advanced renal cell carcinoma soon become brighter?
    D'Hondt V; Gil T; Lalami Y; Piccart M; Awada A
    Eur J Cancer; 2005 Jun; 41(9):1246-53. PubMed ID: 15939260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunological heterogeneity of the RCC microenvironment: do targeted therapies influence immune response?
    Bex A; Etto T; Vyth-Dreese F; Blank C; Griffioen AW
    Curr Oncol Rep; 2012 Jun; 14(3):230-9. PubMed ID: 22362358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-Based Virtual Screening for the Identification of High Affinity Compounds as Potent VEGFR2 Inhibitors for the Treatment of Renal Cell Carcinoma.
    Sharma K; Patidar K; Ali MA; Patil P; Goud H; Hussain T; Nayarisseri A; Singh SK
    Curr Top Med Chem; 2018; 18(25):2174-2185. PubMed ID: 30499413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic therapy in metastatic renal cell carcinoma.
    Pyrhönen SO
    Scand J Surg; 2004; 93(2):156-61. PubMed ID: 15285569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New Insights into Adjuvant Renal Cell Carcinoma Treatment with Vascular Endothelial Growth Factor Inhibitors: What Have We Learned So Far?
    Escudier B; Staehler M
    Eur Urol; 2018 Jan; 73(1):1-3. PubMed ID: 28890247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sunitinib malate for the treatment of renal cell carcinoma.
    Wood L
    Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
    Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
    Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecularly targeted agents for renal cell carcinoma: the next generation.
    Cowey CL; Hutson TE
    Clin Adv Hematol Oncol; 2010 May; 8(5):357-60, 361-4. PubMed ID: 20551895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment options for metastatic renal cell carcinoma: a review.
    Athar U; Gentile TC
    Can J Urol; 2008 Apr; 15(2):3954-66. PubMed ID: 18405442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interview with professor Per-Anders Abrahamson: angiogenesis and renal cell carcinoma.
    Abrahamson PA
    Eur Urol; 2006 Sep; 50(3):609-11. PubMed ID: 16824676
    [No Abstract]   [Full Text] [Related]  

  • 36. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy.
    Saylor PJ; Escudier B; Michaelson MD
    Clin Genitourin Cancer; 2012 Jun; 10(2):77-83. PubMed ID: 22382009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance to angiogenesis inhibitors in renal cell carcinoma.
    Tamaskar I; Dhillon J; Pili R
    Clin Adv Hematol Oncol; 2011 Feb; 9(2):101-10. PubMed ID: 22173604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B
    Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
    Rini BI
    Clin Cancer Res; 2007 Feb; 13(4):1098-106. PubMed ID: 17317817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology.
    Su D; Singer EA; Srinivasan R
    Curr Opin Oncol; 2015 May; 27(3):217-23. PubMed ID: 25811348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.